Abstract
ObjectivesThe aim of this study was to assess the performance of noninvasively prenatal testing (NIPT) for fetal copy number variants (CNVs) in clinical samples, using a whole-genome sequencing method.MethodA total of 919 archived maternal plasma samples with karyotyping/microarray results, including 33 CNVs samples and 886 normal samples from September 1, 2011 to May 31, 2013, were enrolled in this study. The samples were randomly rearranged and blindly sequenced by low-coverage (about 7M reads) whole-genome sequencing of plasma DNA. Fetal CNVs were detected by Fetal Copy-number Analysis through Maternal Plasma Sequencing (FCAPS) to compare to the karyotyping/microarray results. Sensitivity, specificity and were evaluated.Results33 samples with deletions/duplications ranging from 1 to 129 Mb were detected with the consistent CNV size and location to karyotyping/microarray results in the study. Ten false positive results and two false negative results were obtained. The sensitivity and specificity of detection deletions/duplications were 84.21% and 98.42%, respectively.ConclusionWhole-genome sequencing-based NIPT has high performance in detecting genome-wide CNVs, in particular >10Mb CNVs using the current FCAPS algorithm. It is possible to implement the current method in NIPT to prenatally screening for fetal CNVs.
Highlights
Owing to the discovery of fetal cell-free DNA in maternal plasma and rapid development of next-generation sequencing (NGS), noninvasive prenatal testing (NIPT) has brought confound changes to antenatal healthcare in the past few years[1]
33 samples with deletions/duplications ranging from 1 to 129 Mb were detected with the consistent copy number variants (CNVs) size and location to karyotyping/microarray results in the study
It is possible to implement the current method in NIPT to prenatally screening for fetal CNVs
Summary
Owing to the discovery of fetal cell-free DNA (cfDNA) in maternal plasma and rapid development of next-generation sequencing (NGS), noninvasive prenatal testing (NIPT) has brought confound changes to antenatal healthcare in the past few years[1]. The clinical validity and utility of NIPT for testing common aneuploidies have been endorsed by various clinical guidelines for using in high risk pregnancies[2]. Pathogenic CNVs are important contributors of intellectual disabilities in newborns, while in prenatal practice increasing evidence showed that disease-causative CNVs are associated with adverse pregnant outcomes. The risk of CNVs in fetus is independent of maternal age, and younger pregnant women may suffer the risk of pathogenic CNVs as older women[8]. Prenatal testing for clinically significant CNVs may bring benefit to clinical management and genetic counseling of pregnant outcome. Amniocentesis or chorionic villus sampling (CVS) followed by karyotyping or microarray is the major approach to identify fetal CNVs, a small but significant risk of miscarriage is associated with the procedures[9]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
